vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Repay Holdings Corp（RPAY）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是Repay Holdings Corp的1.9倍（$152.6M vs $78.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -178.3%，领先212.8%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs 0.4%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $23.2M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -1.3%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Repay Holdings Corp是一家聚焦北美市场的支付技术服务商，为零售、医疗、汽车服务、电商等领域的企业提供整合支付处理方案，涵盖银行卡收单、ACH转账、POS系统集成等数字化支付工具，助力客户简化交易流程、提升运营效率。
CPRX vs RPAY — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $78.6M |
| 净利润 | $52.7M | $-140.1M |
| 毛利率 | 82.9% | 74.2% |
| 营业利润率 | 40.5% | -182.2% |
| 净利率 | 34.5% | -178.3% |
| 营收同比 | 7.6% | 0.4% |
| 净利润同比 | -5.8% | -3304.1% |
| 每股收益（稀释后） | $0.40 | $-1.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $78.6M | ||
| Q3 25 | $148.4M | $77.7M | ||
| Q2 25 | $146.6M | $75.6M | ||
| Q1 25 | $141.4M | $77.3M | ||
| Q4 24 | $141.8M | $78.3M | ||
| Q3 24 | $128.7M | $79.1M | ||
| Q2 24 | $122.7M | $74.9M | ||
| Q1 24 | $98.5M | $80.7M |
| Q4 25 | $52.7M | $-140.1M | ||
| Q3 25 | $52.8M | $-6.4M | ||
| Q2 25 | $52.1M | $-102.3M | ||
| Q1 25 | $56.7M | $-7.9M | ||
| Q4 24 | $55.9M | $-4.1M | ||
| Q3 24 | $43.9M | $3.2M | ||
| Q2 24 | $40.8M | $-4.1M | ||
| Q1 24 | $23.3M | $-5.2M |
| Q4 25 | 82.9% | 74.2% | ||
| Q3 25 | 84.7% | 74.4% | ||
| Q2 25 | 85.9% | 75.7% | ||
| Q1 25 | 87.3% | 75.9% | ||
| Q4 24 | 84.7% | 76.3% | ||
| Q3 24 | 85.0% | 77.8% | ||
| Q2 24 | 87.4% | 78.2% | ||
| Q1 24 | 87.3% | 76.2% |
| Q4 25 | 40.5% | -182.2% | ||
| Q3 25 | 44.7% | -3.9% | ||
| Q2 25 | 45.2% | -138.7% | ||
| Q1 25 | 44.8% | -4.7% | ||
| Q4 24 | 44.3% | -1.5% | ||
| Q3 24 | 39.6% | -0.9% | ||
| Q2 24 | 44.2% | -4.6% | ||
| Q1 24 | 27.5% | -3.1% |
| Q4 25 | 34.5% | -178.3% | ||
| Q3 25 | 35.6% | -8.3% | ||
| Q2 25 | 35.6% | -135.2% | ||
| Q1 25 | 40.1% | -10.3% | ||
| Q4 24 | 39.4% | -5.3% | ||
| Q3 24 | 34.1% | 4.1% | ||
| Q2 24 | 33.2% | -5.4% | ||
| Q1 24 | 23.6% | -6.5% |
| Q4 25 | $0.40 | $-1.68 | ||
| Q3 25 | $0.42 | $-0.08 | ||
| Q2 25 | $0.41 | $-1.15 | ||
| Q1 25 | $0.45 | $-0.09 | ||
| Q4 24 | $0.44 | $-0.04 | ||
| Q3 24 | $0.35 | $0.03 | ||
| Q2 24 | $0.33 | $-0.04 | ||
| Q1 24 | $0.19 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $115.7M |
| 总债务越低越好 | — | $280.1M |
| 股东权益账面价值 | $954.3M | $484.4M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | 0.58× |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $115.7M | ||
| Q3 25 | $689.9M | $95.7M | ||
| Q2 25 | $652.8M | $162.6M | ||
| Q1 25 | $580.7M | $165.5M | ||
| Q4 24 | $517.6M | $189.5M | ||
| Q3 24 | $442.3M | $168.7M | ||
| Q2 24 | $375.7M | $147.1M | ||
| Q1 24 | $310.4M | $128.3M |
| Q4 25 | — | $280.1M | ||
| Q3 25 | — | $279.5M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $497.6M | ||
| Q4 24 | — | $496.8M | ||
| Q3 24 | — | $496.2M | ||
| Q2 24 | — | $435.6M | ||
| Q1 24 | — | $434.9M |
| Q4 25 | $954.3M | $484.4M | ||
| Q3 25 | $920.2M | $616.9M | ||
| Q2 25 | $856.0M | $633.7M | ||
| Q1 25 | $794.3M | $755.7M | ||
| Q4 24 | $727.6M | $761.3M | ||
| Q3 24 | $660.9M | $754.7M | ||
| Q2 24 | $608.7M | $815.4M | ||
| Q1 24 | $561.4M | $813.8M |
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $971.9M | $1.4B | ||
| Q1 25 | $908.9M | $1.5B | ||
| Q4 24 | $851.4M | $1.6B | ||
| Q3 24 | $772.0M | $1.6B | ||
| Q2 24 | $706.4M | $1.5B | ||
| Q1 24 | $646.7M | $1.5B |
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.65× | ||
| Q3 24 | — | 0.66× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $23.3M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $23.2M |
| 自由现金流率自由现金流/营收 | 29.4% | 29.6% |
| 资本支出强度资本支出/营收 | 0.0% | 0.1% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $90.7M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $23.3M | ||
| Q3 25 | $32.4M | $32.2M | ||
| Q2 25 | $71.3M | $33.1M | ||
| Q1 25 | $60.0M | $2.5M | ||
| Q4 24 | $70.9M | $34.3M | ||
| Q3 24 | $72.9M | $60.1M | ||
| Q2 24 | $64.1M | $31.0M | ||
| Q1 24 | $31.9M | $24.8M |
| Q4 25 | $44.9M | $23.2M | ||
| Q3 25 | — | $32.1M | ||
| Q2 25 | $71.3M | $33.0M | ||
| Q1 25 | — | $2.4M | ||
| Q4 24 | $70.8M | $34.0M | ||
| Q3 24 | $72.6M | $59.8M | ||
| Q2 24 | $64.1M | $30.5M | ||
| Q1 24 | $31.7M | $24.7M |
| Q4 25 | 29.4% | 29.6% | ||
| Q3 25 | — | 41.3% | ||
| Q2 25 | 48.6% | 43.6% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | 49.9% | 43.5% | ||
| Q3 24 | 56.4% | 75.6% | ||
| Q2 24 | 52.3% | 40.7% | ||
| Q1 24 | 32.2% | 30.6% |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.1% | 0.3% | ||
| Q3 24 | 0.2% | 0.3% | ||
| Q2 24 | 0.0% | 0.6% | ||
| Q1 24 | 0.2% | 0.1% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | 18.52× | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
